Streetbeat News

Earnings

NVDA

Nvidia Corp. is set to reveal its next-gen AI chip, the B100, at the GPU Technology Conference (GTC 2024), with expectations of significantly surpassing the performance of its predecessor, the Hopper H200 AI chip. The B100, featuring advanced TSMC CoWoS-L packaging technology and 192GB of memory, is anticipated to more than double the AI performance of Hopper GPUs. Demand for the B100 is expected to outstrip supply, indicating a major upcoming product cycle for Nvidia. The company's stock has seen a significant increase, gaining about 73% year to date.

Portfolio Pulse from Shanthi Rexaline

March 18, 2024 | 9:30 am

QD

Qudian Inc. (NYSE:QD) reported a significant decrease in both earnings and sales for Q4, with earnings per share down 90% to $0.03 from $0.30 YoY, and sales down 61.29% to $8.98M from $23.21M YoY.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 9:02 am

HTZ

Hertz Global Holdings Inc (NASDAQ:HTZ) appointed Gil West, former COO of GM's autonomous driving unit Cruise, as its new CEO. West's appointment is part of Hertz's cost-cutting mission, which includes selling 20,000 electric vehicles due to high repair costs and replacing them with combustion engine cars. Hertz reported a Q4 adjusted EPS loss of $1.36, with revenue growing 7% year on year to $2.18 billion. GM reported a $3.48 billion operating loss at Cruise in 2023.

Portfolio Pulse from Anan Ashraf

March 18, 2024 | 8:43 am

ALTI

CMTL

SAIC

STNE

YY

U.S. stock futures are trading higher, with focus on SAIC, CMTL, ALTI, STNE, and YY due to earnings reports. SAIC and CMTL are expected to report earnings before and after market close respectively, with SAIC anticipated to report $1.43 EPS on $1.64 billion revenue, and CMTL expected at 22 cents EPS on $152.85 million revenue. ALTI reported a Q4 loss of 87 cents per share, with sales at $91.71 million. STNE is projected to post earnings of 30 cents per share on $685.73 million revenue, while YY is expected to report 77 cents EPS on $558.30 million revenue.

Portfolio Pulse from Avi Kapoor

March 18, 2024 | 8:07 am

TSLA

Gary Black, Managing Partner at Future Fund, criticized personal attacks from Tesla fans after he trimmed his stake in Tesla, citing a 50% loss in the company's long-term earnings power. He maintains a $250 price target for Tesla, despite its recent slump. Ross Gerber, CEO of Gerber Kawasaki, also faced criticism but views the slump as a move towards a more reasonable valuation. Both emphasize analysis over hype in valuation.

Portfolio Pulse from Anan Ashraf

March 18, 2024 | 7:35 am

ASML

AVGO

BIDU

MCK

SYK

UBS has identified key sectors poised for technological innovation, including AI, cybersecurity, health tech, Greentech, and fintech, and listed 29 companies expected to see superior earnings growth. Among these, McKesson Corp, Baidu, Stryker, ASML Holding, and Broadcom were highlighted for their potential in their respective fields. The report suggests these sectors and companies are likely to be industry leaders by 2030.

Portfolio Pulse from Benzinga Neuro

March 18, 2024 | 7:14 am

NIU

Niu Technologies (NASDAQ:NIU) reported a significant decrease in both earnings per share and sales for Q4, with EPS down to $(0.23) from $(0.07) YoY and sales dropping to $67.42M from $88.77M YoY.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 7:05 am

GSK

GSK announced that Phase III data for Jemperli (dostarlimab-gxly) combinations show significant potential in treating primary advanced or recurrent endometrial cancer. The combination of dostarlimab-gxly and chemotherapy demonstrated a 31% reduction in risk of death and a 16.4-month improvement in overall survival compared to chemotherapy alone. Additionally, adding Zejula (niraparib) to dostarlimab-gxly maintenance after chemotherapy showed a 37% reduction in risk of disease progression or death and a 6-month improvement in progression-free survival in the MMRp/MSS population.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 6:35 am

AADI

Aadi Bioscience presented new subgroup analysis at the Society of Gynecologic Oncology, showing efficacy and safety of nab-Sirolimus in treating advanced malignant PEComa of gynecologic origin. This subgroup accounted for over half of the patients in the AMPECT study, with additional data suggesting nab-sirolimus as a potential treatment for mTOR-driven gynecologic cancers.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 6:24 am

SAIC

Science Applications International Corporation (NASDAQ:SAIC) is anticipated to report lower Q4 earnings with an expected EPS of $1.46, down from $2.04 year-over-year, and a projected revenue of $1.64 billion, compared to $1.97 billion. A dividend of 37 cents per share is declared, payable on April 26, 2024. Analysts have adjusted their ratings and price targets, reflecting a mixed outlook.

Portfolio Pulse from Avi Kapoor

March 18, 2024 | 6:08 am